Welcome to our dedicated page for LGN news (Ticker: LGN), a resource for investors and traders seeking the latest updates and insights on LGN stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LGN's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LGN's position in the market.
Legence (NASDAQ:LGN) has announced the pricing of its initial public offering, offering 26 million shares of Class A common stock at $28.00 per share. The company expects to raise approximately $688 million in net proceeds after deducting underwriting discounts and commissions.
Trading is set to commence on September 12, 2025, on the Nasdaq Global Select Market under the ticker symbol "LGN". The underwriters have a 30-day option to purchase up to 3.9 million additional shares. The proceeds will be used to repay a portion of outstanding term loan borrowings and for general corporate purposes.
Goldman Sachs and Jefferies are serving as joint lead book-running managers for the offering, which is expected to close on September 15, 2025.
